Of note, genetic as well as pharmacologic inhibition of CSNK1D efficiently represses oncogenic GLI activity in cancer cells resistant to FDA-approved HH pathway inhibitors targeting the essential HH effector SMO. This evidence concerns the gene SMO and cancer.